|
Quest Diagnostics Incorporated is a corporation that provides clinical laboratory services. Founded in 1967 as Metropolitan Pathology Laboratory, Inc., it became an independent corporation with the Quest name on December 31, 1996. In addition to the United States, Quest Diagnostics also runs operations in United Kingdom, Mexico, Brazil, Puerto Rico and a laboratory in India and also has collaborative agreements internationally with various hospitals and clinics. It is a member of the Fortune 500 and the S&P 500, with corporate headquarters located in Madison, New Jersey. The company has approximately 43,000 employees, and generates more than $7.5 billion in revenue and offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease and neurological disorders. ==History== * 1967: Founded by Paul A. Brown, MD as Metropolitan Pathology Laboratory, Inc., in New York. * 1969: Name Changed to MetPath, Inc., in Teaneck, New Jersey. * 1982: MetPath was acquired by what was then known as Corning Glass Works, and subsequently renamed Corning Clinical Laboratories. * 1996: Quest Diagnostics becomes an independent company as a spin-off from Corning. Kenneth Freeman appointed CEO. * 1997: Acquires clinical laboratory division of Branford, CT-based Diagnostic Medical Laboratory, Inc. (DML). * 1999: Acquires SmithKline Beecham Clinical Laboratories; GlaxoSmithKline still holds a large portion of Quest Diagnostics stock. The SmithKline Beecham acquisition includes a joint venture ownership with CompuNet Clinical Laboratory * 2000: Launch of Six Sigma program * 2001: Completes acquisition of Ohio-based MedPlus, Inc. (), a healthcare technology company. * 2002: Completes acquisition of Virginia-based American Medical Laboratories, Inc. (AML) and an affiliated company of AML, LabPortal, Inc., for approximately $500 million in cash. * 2003: Completes acquisition of California-based Unilab Corporation () in a transaction valued at approximately $800 million. * 2005: Completes acquisition of Kansas-based LabOne, Inc. () for approximately $934 million. * 2005: forms a strategic alliance with Ciphergen Biosystems to commercialize novel proteomic tests.〔(【引用サイトリンク】title= Ciphergen Biosystems and Quest Diagnostics Form Strategic Alliance to Develop and Commercialize Tests Using Ciphergen's Proteomics Technology. )〕 * 2006: Completes acquisition of Virginia-based Focus Diagnostics, Inc., an infectious and immunologic disease laboratory, for approximately $185 million in cash. * 2007: Completes acquisition of Sweden-based Hemocue, a point-of-care diagnostic testing company. * 2007: Acquires AmeriPath (and subsidiary Specialty Laboratories) from Welsh, Carson, Anderson & Stowe, becoming the leading provider of cancer diagnostic testing services. * 2011: Acquires Athena Diagnostics from Thermo Fisher Scientific * 2011: Completes acquisition of Celera Corporation, a company that became famous by its sequencing of the Human Genome.〔(Quest Diagnostics Successfully Completes Acquisition of Celera ) May 17, 2011. Celera Corporation. Retrieved 2012-02-16.〕 * 2012: Names former Philips Healthcare CEO Stephen Rusckowski as CEO. * 2012: CEO, Surya Mohapatra, PhD (CEO From May 2004-April 2012) resigns after leading the company for 8 years * 2012: Quest Diagnostics bought all the labs including the business from UMASS Memorial Hospitals in Worcester, MA. * 2014: Acquires Solstas Lab Partners Group (and subsidiaries) * 2014: Acquires Summit Health, Inc. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Quest Diagnostics」の詳細全文を読む スポンサード リンク
|